Drug Trial Radar · NCT05745623
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Dec 27, 2022
Primary completion
Dec 25, 2027
Study completion Dec 25, 2028
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
Conditions
- Advanced Solid Tumors Harboring NTRK Fusion
- Primary Central Nervous System Tumors Harboring NTRK Fusion
Interventions
ICP-723Drug
ICP-723 tablet administered orally,once a day,for every 28 days as one cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Through study completion, an average of 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.